Merck to pay BMS and Ono $625m in patent settlement
Merck has agreed a settlement and licensing agreement with Bristol-Myers Squibb (BMS) and Ono Pharmaceutical under which it will pay the companies $625 million.
The deal was announced on Friday, January 20, and settles patent infringement litigation related to Merck’s PD-1 antibody Keytruda (pembrolizumab).
Kenneth Frazier, CEO of Merck, said: “Today’s announcement eliminates uncertainty and enables us to continue to focus on Keytruda, our immuno-oncology medicine, which is already helping thousands of patients around the world and becoming a foundation for the treatment of cancer through our industry-leading clinical development programme.”
BMS and Ono had asserted in litigation that Merck’s sale of Keytruda infringed the companies’ patents relating to their PD-1 antibody Opdivo (nivolumab).
As part of the agreement, Merck will also pay ongoing royalties on global sales of Keytruda of 6.5% from January 1, 2017 to December 31, 2023. From 2024 to 2026, Merck will have to pay 2.5% in royalties.
Giovanni Caforio, CEO of BMS, said: “BMS and Ono’s agreement with Merck protects our scientific discoveries and validates the strong intellectual property rights we secured as the early innovators in the science of PD-1, a key mechanism in immuno-oncology that has proven to have a transformational impact in cancer care.”
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk